Trial testing ibuprofen for COVID-19 launched in London

  • King’s College London
  • 2 Jun 2020

  • curated by Dawn O'Shea
  • UK Medical News
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

A trial of lipid ibuprofen to reduce the severity and progression of lung injury in patients with SARS-CoV-2 infections has been launched in South London.

The randomised LIBERATE trial is a collaboration between London’s Guy’s & St Thomas’ NHS Foundation Trust, King’s College London and the pharmaceutical organisation, the SEEK Group. It aims to help refine treatment for COVID-19 with an approach that is distinct from vaccines and anti-viral drugs being researched by other groups.

LIBERATE inclusion criteria are:

  • age ≥18 years;
  • hospitalised;
  • confirmed or suspected SARS-CoV-2 infection;
  • National Early Warning Score (NEWS2) ≥3 in a single parameter or NEWS2 >5 overall;
  • acute hypoxemic respiratory failure: PaO2/FiO2 ratio ≤300 or SpO2/FiO2 ratio
  • written informed consent.

Primary outcome measures are worsening respiratory failure, defined as severity of hypoxaemia (PaO2/FiO2 ratio or SpO2/FiO2 ratio) and time to or need for mechanical ventilation (time frame for both, 14 days).

Secondary outcome measures are:

  • overall survival;
  • reduction in proportion of patients who require ventilation;
  • reduction in length of critical care stay;
  • reduction in length of hospital stay;
  • modulation of serum pro- and anti-inflammatory cytokines;
  • reduction in duration of ventilation; and
  • increase in ventilator-free days.

Time frame for secondary outcome measures is 28 days.

Professor Richard Beale, Consultant in Intensive Care Medicine, said: “As a new illness, there are limited treatment options for patients with COVID-19. The clinical trial will assess whether this unique formulation of an established drug benefits patients with COVID-19.”